Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05853718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 8, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 30, 2024 to Dec 30, 2025
    • Study completion date: Dec 30, 2024 to Dec 30, 2025
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
Trial Details
NCT Number NCT05853718
Lead Sponsor First People's Hospital of Hangzhou
Conditions
(from sponsor)		 Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Related terms Hepatitis B, Chronic
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov